{
    "id": 25734,
    "fullName": "SERPINB4 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SERPINB4 mutant indicates an unspecified mutation in the SERPINB4 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 6318,
        "geneSymbol": "SERPINB4",
        "terms": [
            "SERPINB4",
            "LEUPIN",
            "PI11",
            "SCCA-2",
            "SCCA1",
            "SCCA2"
        ]
    },
    "variant": "mutant",
    "createDate": "11/10/2016",
    "updateDate": "11/10/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9197,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, SERPINB4 mutations were associated with prolonged survival following treatment with anti-CTLA4 therapy, such as Yervoy (ipilimumab), in patients with melanoma (PMID: 27668655).",
            "molecularProfile": {
                "id": 26774,
                "profileName": "SERPINB4 mutant"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6986,
                    "pubMedId": 27668655,
                    "title": "Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27668655"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9198,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, SERPINB4 mutations were associated with prolonged survival following treatment with anti-CTLA4 therapy, such as Tremelimumab, in patients with melanoma (PMID: 27668655).",
            "molecularProfile": {
                "id": 26774,
                "profileName": "SERPINB4 mutant"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6986,
                    "pubMedId": 27668655,
                    "title": "Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27668655"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26774,
            "profileName": "SERPINB4 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}